OIM
TSHA icon

Oracle Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

Oracle Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.46M Buy
+265,000
New +$1.29M 0.87% 12

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oracle Investment Management's TSHA Position: Q4 2025 in Review

Oracle Investment Management opened a new position in Taysha Gene Therapies (TSHA) in Q4 2025: 265,000 shares worth $1.46M. The stake represents 0.87% of the portfolio and ranks #12 among its holdings.

195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Oracle Investment Management held 265,000 shares of Taysha Gene Therapies worth $1.46M as of Q4 2025.
  • Taysha Gene Therapies was a new Oracle Investment Management position in Q4 2025.
  • Taysha Gene Therapies made up 0.87% of Oracle Investment Management's portfolio in Q4 2025, its #12 holding.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Oracle Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.